Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche publishes new ovarian cancer drug trial data

Roche publishes new ovarian cancer drug trial data

6th July 2010

Roche has presented new clinical data from a phase III trial of Avastin, its bevacizumab-based therapy for ovarian cancer.

The Medical Research Council-sponsored ICON7 trial was a large-scale international study which aimed to establish the efficacy of Avastin in combination with chemotherapy, compared to a regime of chemotherapy alone.

It was found that Roche’s Avastin-containing regimen was able to provide improved rates of progression-free survival among patients, while no new adverse events were observed.

This comes after the drug previously demonstrated its efficacy when used in combination with carboplatin and paclitaxel during an earlier phase III trial, results from which were published last month.

Dr Hal Barron, executive vice-president of global development and chief medical officer for Roche, said: “It is encouraging that a second phase III study showed that Avastin in combination with chemotherapy followed by the continued use of Avastin alone helped women live longer without their disease getting worse.”

Earlier this week, Roche and development partner Chugai were granted a restricted recommendation from the National Institute for Health and Clinical Excellence for their rheumatoid arthritis drug RoActemra.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.